Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669279 · ClinicalTrials.gov registry record · Phase 4
Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
NCT00669279 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 41 participants.
The verdict
NCT00669279, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether atenolol or controlled release carvedilol lower blood pressure in the body as effectively as in the arm. Blood pressure measured in the aorta, a large blood vessel carrying blood away from the heart, may be a better measure of the harmful effects of high blood pressure on the body's organs. In the past, blood pressure has only been measured in the arms. However, blood pressure in the arms may not accurately reflect the blood pressure in the aorta and thus may mislead doctors treating high blood pressure. For this reason, we are testing whether two different medications for blood pressure, both in a class called beta blockers, have similar effects on blood pressure in the arm and aorta.
Interventions
- DRUG Atenolol
- DRUG Carvedilol CR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00669279
The ClinicalTrials.gov registry entry for NCT00669279 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atenolol is the first listed.
NCT00669279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00669279 about?
NCT00669279 is a clinical study titled "Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure". The purpose of this research study is to determine whether atenolol or controlled release carvedilol lower blood pressure in the body as effectively as in the arm. Blood pressure measured in the aorta, a large blood vessel carrying blood away from the heart, may be a better measure of the harmful ef...
What is the current status of trial NCT00669279?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2008-04. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00669279?
The interventions under investigation include: Atenolol (DRUG), Carvedilol CR (DRUG).
Who is sponsoring clinical trial NCT00669279?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.